Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present two posters at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, on February 24-26, in West Palm Beach, FL. The posters highlight Qynapse’s latest results with QyScore, its commercially-available automated brain image analysis platform, demonstrating the reproducibility of its results and its value to inform the MS diagnostic standard.
Qynapse also recently published technical validation results in Neuroimage: Clinical (P. Tran et al., 2022, https://doi.org/10.1016/j.nicl.2022.102940), demonstrating the high performance of QyScore® for the automated quantification of white matter hyperintensities in comparison to state-of-the-art methods for both elderly and MS patients.
Recommended AI News: HARMAN Acquires Mixed Reality Pioneer Apostera
“Variability and subjectivity persist in the radiological assessment of MRI biomarkers, which are core components of the MS diagnostic workup and monitoring of disease progression. Today, this can be addressed by more systematically integrating the use of automated methods in clinical practice, to drive better clinical care and outcomes for MS patients,” said Dr. Charles R. G. Guttmann, MD, Director of the Center for Neurological Imaging at Brigham and Women’s Hospital and Associate Professor of Radiology at the Harvard Medical School.
Adam J. Schwarz, PhD (CSO at Qynapse) will present the two poster presentations at ACTRIMS Forum and will be joined on-site by Scott Keddy, MBA (VP of Business Development).
Recommended AI News: Creator Economy Platform Koji Announces $20 Million Series B Fundraise
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.